filmov
tv
Is Trametinib a New Standard for Low-Grade Serous Ovarian Cancer?
Показать описание
Is Trametinib a New Standard for Low-Grade Serous Ovarian Cancer?
A New Standard for Stage 3 BRAF+ Melanoma
The success of the dabrafenib and trametinib combination in BRAF-mutated melanoma
David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC
Trametinib: new treatment for recurrent LGSOC
Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
The METRIC trial of trametinib, five years on
Updates from COMBI-AD: dabrafenib and trametinib for melanoma
Dabrafenib and Trametinib in BRAF-Mutated NSCLC
Dr. Rodabe N. Amaria on Dabrafenib Plus Trametinib in Melanoma
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade...
Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma
Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma
Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma
Practical Experience With Dabrafenib/Trametinib in NCSLC
Recent Advances in the Treatment Landscape of Melanoma
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma
BRAF: A New Target to Treat in Lung Cancer
A Comprehensive Guide to the New Standard of Care for Uveal Melanoma
Dabrafenib plus trametinib improves melanoma patients’ survival
Latest updates in low grade serous ovarian cancer treatment and research
Dabrafenib/Trametinib for BRAF V600E Mutation-Positive Advanced NSCLC (BMIC-018)
Clinical trial updates on patient responses with triplet therapy
What's New in Melanoma - Dr. Bartosz Chmielowski, MD | UCLA Primary Care Update 2015
Комментарии